Physician profile
Vinutha Reddy
NPI 1417052416
$12,279.68
in general payments reported to CMS, 2019-2025
21 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,409 · 2020: $552 · 2021: $1,008 · 2022: $1,366 · 2023: $961 · 2024: $499 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $6,719.64 | 2019-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,107.15 | 2020-2024 | Caplyta |
| Abbvie INC. | $892.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $764.24 | 2019-2024 | Rexulti, Abilify Asimtufii |
| Allergan, INC. | $482.63 | 2019-2020 | |
| Lundbeck LLC | $386.96 | 2019-2023 | Rexulti |
| Axsome Therapeutics, INC. | $333.34 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $304.86 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $266.85 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $215.52 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $184.84 | 2019-2023 | Invega Trinza, Invega Sustenna |
| Indivior INC. | $128.90 | 2019-2025 | Sublocade, Perseris |
| Teva Pharmaceuticals USA, INC. | $123.77 | 2023-2024 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $121.60 | 2025 | Fanapt |
| Bausch Health US, LLC | $98.74 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.61 | 2019-2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $24.94 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Shire North American Group INC | $15.18 | 2019 | |
| Tris Pharma INC | $15.00 | 2024 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinutha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.